| MDMA | Q69488 |
| scholarly article | Q13442814 |
| P2093 | author name string | E B De Souza | |
| M J Kuhar | |||
| G Battaglia | |||
| M E Molliver | |||
| E O'Hearn | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neurotoxicity | Q3338704 |
| P304 | page(s) | 2788-2803 | |
| P577 | publication date | 1988-08-01 | |
| P1433 | published in | Journal of Neuroscience | Q1709864 |
| P1476 | title | Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity | |
| P478 | volume | 8 |
| Q37479246 | (±)3,4-methylenedioxymethamphetamine ("ecstasy") treatment modulates expression of neurotrophins and their receptors in multiple regions of adult rat brain. |
| Q34424134 | 2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations |
| Q28270011 | 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine |
| Q34565712 | 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings |
| Q28568813 | 3,4-Methylenedioxymethamphetamine increases pro-interleukin-1beta production and caspase-1 protease activity in frontal cortex, but not in hypothalamus, of Dark Agouti rats: role of interleukin-1beta in neurotoxicity |
| Q48700871 | 3,4-methylenedioxyamphetamine (MDA) self-administration and neurotoxicity |
| Q34437998 | 3,4-methylenedioxymethamphetamine (MDMA): a review |
| Q43581726 | 3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. |
| Q47816087 | 3-4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function |
| Q28268394 | 5-iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine |
| Q48622884 | A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat |
| Q35026311 | A study of the neurotoxic effect of MDMA ('ecstasy') on 5-HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy |
| Q40379051 | A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons |
| Q40518413 | Acute and long-term effects of ecstasy |
| Q48502115 | Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on 5-HT cell firing and release: comparison between dorsal and median raphe 5-HT systems |
| Q39372432 | Adolescent intermittent ethanol reduces serotonin expression in the adult raphe nucleus and upregulates innate immune expression that is prevented by exercise |
| Q41180408 | Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'). |
| Q34026981 | Age differences in (±) 3,4-methylenedioxymethamphetamine (MDMA)-induced conditioned taste aversions and monoaminergic levels. |
| Q48824498 | Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ("Ecstasy"). |
| Q42518331 | Altered forebrain neurotransmitter responses to immobilization stress following 3,4-methylenedioxymethamphetamine |
| Q48301587 | Altered pain responses in abstinent (±)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users. |
| Q48188496 | Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery |
| Q67676454 | Aminergic Metabolites in Cerebrospinal Fluid of Humans Previously Exposed to MDMA: Preliminary Observations |
| Q34102002 | Amphetamine toxicities: classical and emerging mechanisms. |
| Q68305349 | Assessment of the role of α-methylapinine in the neurotoxicity of MDMA |
| Q35836300 | Axonal targeting of the serotonin transporter in cultured rat dorsal raphe neurons is specified by SEC24C-dependent export from the endoplasmic reticulum |
| Q40602429 | Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat. |
| Q46140158 | Beta-amyloid cortical deposits are accompanied by the loss of serotonergic neurons in the dog. |
| Q40467154 | Binge ethanol administration enhances the MDMA-induced long-term 5-HT neurotoxicity in rat brain. |
| Q35237299 | Brain serotonergic circuitries |
| Q33554672 | Catechol-o-methyltransferase and 3,4-({+/-})-methylenedioxymethamphetamine toxicity |
| Q35594881 | Causes and consequences of methamphetamine and MDMA toxicity |
| Q41694692 | Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners |
| Q44410467 | Cerebral activation in abstinent ecstasy (MDMA) users during a working memory task: a functional magnetic resonance imaging (fMRI) study |
| Q41885785 | Changes in interleukin-1 signal modulators induced by 3,4-methylenedioxymethamphetamine (MDMA): regulation by CB2 receptors and implications for neurotoxicity |
| Q34184343 | Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. |
| Q48932276 | Chronic alcoholism in the absence of Wernicke-Korsakoff syndrome and cirrhosis does not result in the loss of serotonergic neurons from the median raphe nucleus |
| Q34535259 | Clinical applications of hallucinogens: A review |
| Q37789757 | Cocaine, metamfetamine, and MDMA abuse: the role and clinical importance of neuroadaptation |
| Q31118919 | Comparison of the effects of repeated oral versus subcutaneous fenfluramine administration on rat brain monoamine neurons: Pharmacokinetic and dose-response data |
| Q99202953 | Comprehensive Topographical Map of the Serotonergic Fibers in the Male Mouse Brain |
| Q44691878 | DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy). |
| Q57176236 | Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine |
| Q46763655 | Decrease in REM latency and changes in sleep quality parallel serotonergic damage and recovery after MDMA: a longitudinal study over 180 days |
| Q43179075 | Deficits of long-term memory in ecstasy users are related to cognitive complexity of the task |
| Q34272766 | Designer drugs: how dangerous are they? |
| Q48509443 | Differential development of the dual serotoninergic fiber system in the cerebral cortex of the cat |
| Q73222858 | Differential polarization of serotonin transporters in axons versus soma-dendrites: an immunogold electron microscopy study |
| Q34645756 | Dissociation of the neurochemical and behavioral toxicology of MDMA ('Ecstasy') by citalopram |
| Q48933985 | Distribution of two morphologically distinct subsets of serotoninergic axons in the cerebral cortex of the marmoset |
| Q28370860 | Dual serotonin (5-HT) projections to the nucleus accumbens core and shell: relation of the 5-HT transporter to amphetamine-induced neurotoxicity |
| Q41150965 | Dual serotoninergic projections to forebrain in the rat: Morphologically distinct 5-HT axon terminals exhibit differential vulnerability to neurotoxic amphetamine derivatives |
| Q36118481 | Dystrophic serotonergic axons in neurodegenerative diseases. |
| Q41136324 | Effect of 3,4-Methylenedioxymethamphetamine on 3,4-Dihydroxyphenylalanine Accumulation in the Striatum and Nucleus Accumbens |
| Q48359152 | Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin |
| Q40541816 | Effect of 5-HT depletion by MDMA on hyperthermia and Arc mRNA induction in rat brain |
| Q31561882 | Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain |
| Q52237736 | Effect of MDMA neurotoxicity upon its conditioned place preference and discrimination |
| Q28548147 | Effect of MDMA-Induced Axotomy on the Dorsal Raphe Forebrain Tract in Rats: An In Vivo Manganese-Enhanced Magnetic Resonance Imaging Study |
| Q44730978 | Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA. |
| Q55066895 | Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin. |
| Q45224213 | Effect of ecstasy use on neuropsychological function: a study in Hong Kong |
| Q36875417 | Effects of a short-course MDMA binge on dopamine transporter binding and on levels of dopamine and its metabolites in adult male rats. |
| Q44843771 | Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA. |
| Q25256757 | Electrocortical effects of MDMA are potentiated by acoustic stimulation in rats |
| Q46902890 | Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ("Ecstasy"). |
| Q48250458 | Ethanol-MDMA interactions in rats: the importance of interval between repeated treatments in biobehavioral tolerance and sensitization to the combination |
| Q36645266 | Evaluation of Bcl-2 Family Gene Expression in Hippocampus of 3, 4-methylenedioxymethamphetamine Treated Rats. |
| Q35757409 | Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons |
| Q73387773 | Expression of serotonin transporter protein in developing rat brain |
| Q41738674 | Free radicals and the pathobiology of brain dopamine systems |
| Q35044762 | Functional consequences of perinatal exposure to 3,4-methylenedioxymethamphetamine in rat brain |
| Q34389463 | Glial cell response to 3,4-(+/-)-methylenedioxymethamphetamine and its metabolites |
| Q34558846 | How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? |
| Q46789654 | Immunocytochemical evidence for methamphetamine-induced serotonergic axon loss in the rat brain |
| Q30495577 | Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) |
| Q48226317 | In vivo evidence against clomethiazole being neuroprotective against MDMA ('ecstasy')-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism |
| Q42261569 | In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine |
| Q67650201 | In vivo formation of aromatic hydroxylated metabolites of 3,4-(methylenedioxy)methamphetamine in the rat: Identification by ion trap tandem mass spectrometric (MS/MS and MS/MS/MS) techniques |
| Q44050776 | Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion |
| Q41364931 | Increased interleukin-1β levels following low dose MDMA induces tolerance against the 5-HT neurotoxicity produced by challenge MDMA. |
| Q46857178 | Initial deficit and recovery of function after MDMA preexposure in rats |
| Q21091087 | Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans |
| Q73295552 | Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine |
| Q51082984 | Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. |
| Q46923743 | Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines |
| Q44212244 | Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study. Magnetic resonance spectroscopy |
| Q47888045 | MDMA ('Ecstasy') enhances 5-HT1A receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion |
| Q34280047 | MDMA administration decreases serotonin but not N-acetylaspartate in the rat brain |
| Q44212255 | MDMA alters the response of the circadian clock to a photic and non-photic stimulus |
| Q48095503 | MDMA induces EPSP-Spike potentiation in rat ventral hippocampus in vitro via serotonin and noradrenaline release and coactivation of 5-HT4 and beta1 receptors |
| Q35940652 | MDMA-induced loss of parvalbumin interneurons within the dentate gyrus is mediated by 5HT2A and NMDA receptors |
| Q34792272 | Major metabolites of(±)3,4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons |
| Q31840658 | Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. |
| Q48233559 | Methylenedioxyamphetamine: neurotoxic effects on serotonergic projections to brainstem nuclei in the rat |
| Q73371204 | Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms |
| Q55043421 | Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): Neurodegeneration versus Neuromodulation. |
| Q48686930 | Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues |
| Q34976260 | Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. |
| Q58330323 | Monoamine Oxidase-B Mediates Ecstasy-Induced Neurotoxic Effects to Adolescent Rat Brain Mitochondria |
| Q48588523 | Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships |
| Q35165280 | Monoamine reuptake inhibitors in Parkinson's disease |
| Q40535965 | Neonatal 3,4-methylenedioxymethamphetamine (ecstasy) alters dopamine and serotonin neurochemistry and increases brain-derived neurotrophic factor in the forebrain and brainstem of the rat. |
| Q24619949 | Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA) |
| Q36539089 | Neuroimaging research in human MDMA users: a review |
| Q30417935 | Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine |
| Q44865152 | Neurotoxicity of methamphetamine and methylenedioxymethamphetamine |
| Q36797987 | Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms |
| Q28553620 | Non-Serotonergic Neurotoxicity by MDMA (Ecstasy) in Neurons Derived from Mouse P19 Embryonal Carcinoma Cells |
| Q46585310 | Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons |
| Q42467656 | Pineal serotonin is resistant to depletion by serotonergic neurotoxins in rats |
| Q48355353 | Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings |
| Q72113788 | Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists |
| Q44675333 | Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects |
| Q44583496 | Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats |
| Q44123284 | Preprotachykinin A gene expression after administration of 3,4-methylene dioxymethamphetamine (Ecstasy). |
| Q73290370 | Priapism: ecstasy related? |
| Q28569725 | Prior exposure to chronic stress and MDMA potentiates mesoaccumbens dopamine release mediated by the 5-HT(1B) receptor |
| Q33877774 | Pro-oxidant effects of Ecstasy and its metabolites in mouse brain synaptosomes |
| Q35709424 | Projections and interconnections of genetically defined serotonin neurons in mice. |
| Q72232854 | Psychostimulants |
| Q24678394 | Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB |
| Q73065128 | Rat strain differences in the vulnerability of serotonergic nerve endings to neurotoxic damage by p-chloroamphetamine |
| Q51887349 | Rats preexposed to MDMA display attenuated responses to its aversive effects in the absence of persistent monoamine depletions. |
| Q74014790 | Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss |
| Q41580785 | Regrowth of Serotonin Axons in the Adult Mouse Brain Following Injury |
| Q44784005 | Repeated exposure to MDMA and amphetamine: sensitization, cross-sensitization, and response to dopamine D₁- and D₂-like agonists |
| Q37368451 | Repeated exposure to MDMA provides neuroprotection against subsequent MDMA-induced serotonin depletion in brain |
| Q48456238 | Repeated exposure to methylenedioxymethamphetamine (MDMA) alters nucleus accumbens neuronal responses to dopamine and serotonin |
| Q41968944 | Repeated injection of cocaine potentiates methamphetamine-induced toxicity to dopamine-containing neurons in rat striatum |
| Q46679299 | Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users. |
| Q40483217 | Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). |
| Q36803318 | Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users |
| Q38677415 | Schizophrenia: a disease of interhemispheric processes at forebrain and brainstem levels? |
| Q30431654 | Serotonergic dystrophy induced by excess serotonin |
| Q47769778 | Serotonin axons in the neocortex of the adult female mouse regrow after traumatic brain injury. |
| Q34607458 | Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue |
| Q33652473 | Serotonin reuptake transporter deficiency modulates the acute thermoregulatory and locomotor activity response to 3,4-(±)-methylenedioxymethamphetamine, and attenuates depletions in serotonin levels in SERT-KO rats |
| Q30430944 | Serotonin: a regulator of neuronal morphology and circuitry |
| Q34196259 | Short- and long-term effects of MDMA (“ecstasy”) on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo |
| Q45053309 | Single oral doses of (±) 3,4-methylenedioxymethamphetamine ('Ecstasy') produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations |
| Q48721994 | Site-specific regulation of corticosteroid and serotonin receptor subtype gene expression in the rat hippocampus following 3,4-methylenedioxymethamphetamine: role of corticosterone and serotonin |
| Q37465039 | Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers |
| Q34618285 | Sleep deprivation differentially impairs cognitive performance in abstinent methylenedioxymethamphetamine ("Ecstasy") users |
| Q48444036 | Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. |
| Q44019771 | Specific neurotoxicity of chronic use of ecstasy |
| Q36573258 | Studies of (±)-3,4-methylenedioxymethamphetamine (MDMA) metabolism and disposition in rats and mice: relationship to neuroprotection and neurotoxicity profile |
| Q42008895 | Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration |
| Q48107048 | Synaptic structure and connectivity of serotonin terminals in the ventral tegmental area: potential sites for modulation of mesolimbic dopamine neurons |
| Q44590396 | Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy). |
| Q37925507 | The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis |
| Q42472397 | The ascending serotonergic system in the hamster: comparison with projections of the dorsal and median raphe nuclei. |
| Q48149811 | The distribution of 3,4-methylenedioxymethamphetamine "Ecstasy"-induced c-fos expression in rat brain |
| Q40550534 | The effect of 3,4-methylenedioxymethamphetamine ('Ecstasy') on serotonergic regulation of the mammalian circadian clock mechanism in rats: the role of dopamine and hyperthermia |
| Q74315847 | The effect of fenfluramine dosage regimen and reduced food intake on levels of 5-HT in rat brain |
| Q34463526 | The effects of ecstasy (MDMA) on brain serotonin transporters are dependent on age-of-first exposure in recreational users and animals |
| Q28069364 | The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies |
| Q35872606 | The hyperthermic and neurotoxic effects of ‘Ecstasy’ (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype |
| Q28346708 | The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain |
| Q36862351 | The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release |
| Q21558652 | The neurotoxicity of amphetamines during the adolescent period |
| Q48811586 | The organization of serotonergic projections to cerebral cortex in primates: Regional distribution of axon terminals |
| Q41140715 | The organization of serotonergic projections to cerebral cortex in primates: Retrograde transport studies |
| Q37245998 | The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse |
| Q22252794 | Toxicity of amphetamines: an update |
| Q33864805 | Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). |
| Q59619133 | Ultrastructural characterization of tryptophan hydroxylase 2-specific cortical serotonergic fibers and dorsal raphe neuronal cell bodies after MDMA treatment in rat |
| Q48231652 | Ultrastructure of serotonin-immunoreactive terminals in the core and shell of the rat nucleus accumbens: cellular substrates for interactions with catecholamine afferents |
| Q38362000 | Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. |
| Q48908134 | Unlike systemic administration of p-chloroamphetamine, direct intracerebral injection does not produce degeneration of 5-HT axons |
| Q36686106 | Use of quantitative ultrastructural immunoperoxidase labeling for analysis of catecholamine neurotoxicity and plasticity |
| Q41665108 | p-Chloroamphetamine (PCA), 3,4-methylenedioxy-methamphetamine (MDMA) and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT in vivo. |
Search more.